Japan Signs ¥112 Billion Flu Vaccine Deal With GSK And Novartis
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare announced Oct. 6 the signing of new flu vaccine purchasing agreements with GlaxoSmithKline and Novartis
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.